SCHEMBL5757204

SCHEMBL5757204

CCCCN(CCO)S(=O)(=O)c1ccc(Cc2ccc3oc(=O)cc(C(F)(F)F)c3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
TP53 P04637 3/20 0.41
MAPT P10636 3/20 0.38
ALDH1A1 P00352 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
POLB P06746 3/20 0.37
MCL1 Q07820 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP1B1 Q16678 1/20 0.36
VCAM1 P19320 1/20 0.36
HSD17B3 P37058 1/20 0.35
PPARA Q07869 2/20 0.35
AR P10275 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5758908 0.97 TP53 (0.39) LMNATP53MAPTALDH1A1NPSR1
SCHEMBL5761676 0.96 LMNA (0.44) LMNATP53MAPTALDH1A1NPSR1
SCHEMBL5761174 0.95 MCL1 (0.37) LMNATP53MAPTALDH1A1NPSR1
SCHEMBL5760662 0.93 KDM4E (0.41) LMNATP53MAPTALDH1A1NPSR1
SCHEMBL5860102 0.88 AR (0.39) LMNATP53ALDH1A1NPSR1GAA
SCHEMBL5758868 0.86 NR1H4 (0.43) LMNAMAPTALDH1A1NPSR1TSHR
SCHEMBL5860528 0.82 AR (0.40) ALDH1A1CYP1A1CYP1A2CYP1B1AR
SCHEMBL5761340 0.81 MEN1 (0.39) LMNAALDH1A1NPSR1MCL1MEN1
SCHEMBL5762598 0.80 TSHR (0.50) LMNATP53MAPTALDH1A1NPSR1
SCHEMBL5761235 0.80 AR (0.46) NPSR1TSHRMEN1KMT2AAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT LMNA 3279/4885TP53 1975/4885MAPT 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.